Gilead Sciences GILD Stock
Gilead Sciences Price Chart
Gilead Sciences GILD Financial and Trading Overview
| Gilead Sciences stock price | 66.64 USD |
| Previous Close | 78.93 USD |
| Open | 79.2 USD |
| Bid | 79.08 USD x 800 |
| Ask | 79.68 USD x 1000 |
| Day's Range | 79.16 - 80 USD |
| 52 Week Range | 72.87 - 88.29 USD |
| Volume | 4.11M USD |
| Avg. Volume | 6.2M USD |
| Market Cap | 99.26B USD |
| Beta (5Y Monthly) | 0.309 |
| PE Ratio (TTM) | 17.057816 |
| EPS (TTM) | 4.5 USD |
| Forward Dividend & Yield | 3 (3.76%) |
| Ex-Dividend Date | December 14, 2023 |
| 1y Target Est | 80.98 USD |
GILD Valuation Measures
| Enterprise Value | 116.2B USD |
| Trailing P/E | 17.057816 |
| Forward P/E | 12.069697 |
| PEG Ratio (5 yr expected) | 3.43 |
| Price/Sales (ttm) | 3.6238017 |
| Price/Book (mrq) | 4.4517717 |
| Enterprise Value/Revenue | 4.242 |
| Enterprise Value/EBITDA | 9.899 |
Trading Information
Gilead Sciences Stock Price History
| Beta (5Y Monthly) | 0.309 |
| 52-Week Change | N/A |
| S&P500 52-Week Change | N/A |
| 52 Week High | 88.29 USD |
| 52 Week Low | 72.87 USD |
| 50-Day Moving Average | 78.07 USD |
| 200-Day Moving Average | 78.24 USD |
GILD Share Statistics
| Avg. Volume (3 month) | 6.2M USD |
| Avg. Daily Volume (10-Days) | 7.93M USD |
| Shares Outstanding | 1.25B |
| Float | 1.24B |
| Short Ratio | 2.71 |
| % Held by Insiders | 0.073% |
| % Held by Institutions | 87.84% |
| Shares Short | 17.42M |
| Short % of Float | 1.55% |
| Short % of Shares Outstanding | 1.39% |
Dividends & Splits
| Trailing Annual Dividend Rate | 2.98 |
| Trailing Annual Dividend Yield | 3.77% |
| 5 Year Average Dividend Yield | 395.00% |
| Payout Ratio | 0.6381 |
| Last Split Factor | 2:1 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | September 30, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 21.45% |
| Operating Margin (ttm) | 38.51% |
| Gross Margin | 78.81% |
| EBITDA Margin | 42.85% |
Management Effectiveness
| Return on Assets (ttm) | 9.21% |
| Return on Equity (ttm) | 26.92% |
Income Statement
| Revenue (ttm) | 27.39B USD |
| Revenue Per Share (ttm) | 21.9 USD |
| Quarterly Revenue Growth (yoy) | 0.10% |
| Gross Profit (ttm) | 21.62B USD |
| EBITDA | 11.74B USD |
| Net Income Avi to Common (ttm) | 5.88B USD |
| Diluted EPS (ttm) | 4.67 |
| Quarterly Earnings Growth (yoy) | 21.89% |
Balance Sheet
| Total Cash (mrq) | 7.97B USD |
| Total Cash Per Share (mrq) | 6.4 USD |
| Total Debt (mrq) | 24.98B USD |
| Total Debt/Equity (mrq) | 112.32 USD |
| Current Ratio (mrq) | 1.338 |
| Book Value Per Share (mrq) | 17.894 |
Cash Flow Statement
| Operating Cash Flow (ttm) | 8.4B USD |
| Levered Free Cash Flow (ttm) | 9.22B USD |
Profile of Gilead Sciences
| Country | United States |
| State | CA |
| City | Foster City |
| Address | 333 Lakeside Drive |
| ZIP | 94404 |
| Phone | 650 574 3000 |
| Website | https://www.gilead.com |
| Industry | Drug Manufacturers-General |
| Sector(s) | Healthcare |
| Full Time Employees | 17000 |
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Merck & Co, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Merck & Co, Inc., and Tentarix Biotherapeutics Inc., as well as a partnership with Assembly Biosciences, Inc. to develop next-generation therapeutics for serious viral diseases. The company was incorporated in 1987 and is headquartered in Foster City, California.
Q&A For Gilead Sciences Stock
What is a current GILD stock price?
Gilead Sciences GILD stock price today per share is 66.64 USD.
How to purchase Gilead Sciences stock?
You can buy GILD shares on the NasdaqGS exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Gilead Sciences?
The stock symbol or ticker of Gilead Sciences is GILD.
Which industry does the Gilead Sciences company belong to?
The Gilead Sciences industry is Drug Manufacturers-General.
How many shares does Gilead Sciences have in circulation?
The max supply of Gilead Sciences shares is 1.27B.
What is Gilead Sciences Price to Earnings Ratio (PE Ratio)?
Gilead Sciences PE Ratio is 15.12666700 now.
What was Gilead Sciences earnings per share over the trailing 12 months (TTM)?
Gilead Sciences EPS is 4.5 USD over the trailing 12 months.
Which sector does the Gilead Sciences company belong to?
The Gilead Sciences sector is Healthcare.
Gilead Sciences GILD included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 16175.09 USD — |
-1.62
|
3.94B USD — | 16125.33 USD — | 16341.46 USD — | — - | 3.94B USD — |
| S&P 500 INDEX SPX | 5123.41 USD — |
-1.46
|
2.41B USD — | 5107.94 USD — | 5175.03 USD — | — - | 2.41B USD — |
| S&P 500 (Yahoo.com) GSPC | 5123.41 USD — |
-1.46
|
2.41B USD — | 5107.94 USD — | 5175.03 USD — | — - | 2.41B USD — |
| S&P 100 SP100 | 2432.83 USD — |
-1.42
|
1.22B USD — | 2425.59 USD — | 2456.62 USD — | — - | 1.22B USD — |
| US100 NDX | 18003.49 USD — |
-1.66
|
866.13M USD — | 17952.09 USD — | 18166.49 USD — | — - | 866.13M USD — |
| Dow Jones U.S. Biotechnology In DJUSBT | 2713.11 USD — |
-2.04
|
67.04M USD — | 2703.19 USD — | 2755.25 USD — | — - | 67.04M USD — |
| Nasdaq US Smart Pharmaceuticals NQSSPH | 1383.38 USD — |
-2.07
|
— — | 1380.57 USD — | 1408.57 USD — | — - | — — |
| Nasdaq AlphaDEX Multi Cap Growt NQDXUSMLTCG | 2541.54 USD — |
-1.89
|
— — | 2531.95 USD — | 2572.66 USD — | — - | — — |
| Nasdaq CRD Global Sustainabilit NQCRD | 1735.62 USD — |
0
|
— — | 1715.94 USD — | 1757.95 USD — | — - | — — |
| The Capital Strength Index seek NQCAPST | 3005.23 USD — |
-1.04
|
— — | 2995.36 USD — | 3025.3 USD — | — - | — — |
| Nasdaq-100 ESG Net Notional Tot NDXESG24 | 1502.41 EUR 1642.34 USD |
-0.99
|
— — | 1496.77 EUR 1636.17 USD | 1514.56 EUR 1655.62 USD | — - | — — |
| NASDAQ-100 PM Settlement Value XQC | 16331.98 USD — |
+1.13
|
— — | 16331.98 USD — | 16331.98 USD — | — - | — — |
| NASDAQ Composite Total Return I XCMP | 19659.36 USD — |
-1.62
|
— — | 19598.88 USD — | 19861.56 USD — | — - | — — |
| NASDAQ 100 Equal Weighted NDXE | 7278.7 USD — |
-1.88
|
— — | 7263.41 USD — | 7351.66 USD — | — - | — — |
| NASDAQ 100 Notional Net Total R XNDXNNR | 20733.49 USD — |
-1.66
|
— — | 20674.3 USD — | 20921.22 USD — | — - | — — |
- {{ link.label }} {{link}}